• People
  • Web mail
  • Internal and Reserved Area
  • Print

Dr. Maria Cristina Messa

Tecnomed Foundation, University of Milano-Bicocca, San Gerardo Hospital, Monza

Friday, July 6th, 2012 at 11:00:00 AM  

Conference room Querzoli - LENS - via Nello Carrara 1 - Sesto Fiorentino (Florence)

Enrico Fermi Colloquium

Published on-line at 05:24:11 PM on Thursday, June 14th, 2012

Imaging in the era of molecular medicine in humans

Research in molecular medicine is rapidly developing toward the use of nanotechnology in order to build more specific and dual-modality imaging probes.

Molecular medicine is rapidly changing most of the well established protocols that have been used for the past decades to classify diseases and to address therapy. In particular, the present and future clinical needs in major diseases, such as oncological, cardiovascular and neurodegenerative disorders, will be focused on characterising different genotypes and phenotypes underlying information can be provided, in vivo and in human subjects, by molecular imaging methods, such as Positron Emission Tomography (PET) and Magnetic Resonance (MR) imaging.

These technologies are already changing the management of many diseases, including cancer, where they can define different aspects of disease (morphology, function, biochemistry) in a high accurate manner with the aim of addressing therapy in a personalised manner. Thus, expectancies from the PET and MR methods are very high and the technological development has to focus on finding new probes. Many new radioligands have been proposed particularly important for oncological studies that are now ready to be applied to study large population of patients. In particular these studies include studies of tumor hypoxia and neo-angiogenesis as well as studies of specific tumor's markers. Furthermore, the research in this field is rapidly developing toward the use of nanotechnology in order to build more specific and dual-modality imaging probes, that, taking full advantage from two different imaging modalities, eg PET and MR, may provide unique information for the preclinical and possibly the clinical diagnosis.

Finally, the development of drugs can be effectively guided by molecular imaging and might take advantage from the use of nanotechnologies particularly to improve mechanisms of delivery (image from http://dx.doi.org/10.1016/j.eururo.2010.09.004).

[video=720 540]b20120706_messa[/video]

Klein Colloquium by Giacomo Valtolina (Università degli Studi di Milano-Bicocca and LENS): "Ultracold newcomers at LENS".

[video=720 540]a20120706_valtolina[/video]